TCGA-IQ-7632-01A-11R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.400
- MYC_TARGETS_V2+0.360
- PROTEIN_SECRETION+0.350
- CHOLESTEROL_HOMEOSTASIS+0.340
- ANDROGEN_RESPONSE+0.320
- P53_PATHWAY+0.310
- MYC_TARGETS_V1+0.300
- FATTY_ACID_METABOLISM+0.290
- PANCREAS_BETA_CELLS+0.280
- ADIPOGENESIS+0.260
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- MYOGENESIS-0.290
- HEDGEHOG_SIGNALING-0.270
- INTERFERON_ALPHA_RESPONSE-0.270
- IL6_JAK_STAT3_SIGNALING-0.220
- ANGIOGENESIS-0.210
- INFLAMMATORY_RESPONSE-0.210
- E2F_TARGETS-0.200
- INTERFERON_GAMMA_RESPONSE-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | da1c4d8d-b07a-4aa1-8360-1c140ca16327 | — | — | 0.872 |
| 2 | bf93be3e-d4f1-4efb-9841-ca8ad81b237e | — | — | 0.825 |
| 3 | ULC1452T_S57 | — | cohortA1 | 0.805 |
| 4 | e94b6daf-3aed-4496-b64b-1b1a7d8e2011 | — | — | 0.797 |
| 5 | 3d6b96fa-5efa-4c8a-9a12-2718304252d4 | — | — | 0.796 |
| 6 | TCGA-CF-A3MG-01A-11R-A20F-07 | — | — | 0.759 |
| 7 | 79a36f11-38bb-42ed-a95a-ae2a9eea0f6a | — | — | 0.737 |
| 8 | SRR8518238 | — | C | 0.733 |
| 9 | 56D3154E-E779-4C27-8305-FEE7310B6762 | — | — | 0.732 |
| 10 | BS_TBWYAFSM | Spinal Cord Ependymoma | — | 0.732 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |